依鲁替尼对flt3-itd突变的急性白血病的应用

Use of ibrutinib for flt3-itd mutational acute leukemia

Utilisation d'ibrutinib pour une leucémie aiguë avec mutation flt3-itd

Abstract

公开了依鲁替尼(PCI32765)的一种新用途,具体地发现依鲁替尼可以用于治疗急性髓细胞白血病,特别是携带FLT3/ITD突变型基因的急性髓细胞白血病。
La présente invention concerne une nouvelle utilisation de l'ibrutinib (PCI32765). Il s'avère notamment que l'ibrutinib peut être utilisé pour traiter une leucémie myéloïde aiguë, notamment une leucémie myéloïde aiguë portant un gène mutant FLT3/ITD.
Disclosed is a new use of ibrutinib (PCI32765). It is particularly found that ibrutinib can be used for treating acute myeloid leukemia, especially acute myeloid leukemia carrying an FLT3/ITD mutant gene.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (1)

    Publication numberPublication dateAssigneeTitle
    CN-104039325-ASeptember 10, 2014药品循环公司Use of inhibitors of bruton's tyrosine kinase (btk)

NO-Patent Citations (4)

    Title
    MA, DAWEI ET AL.: "The expression of Acute myelogenous leukemia FLT3-ITD gene and its clinical significance", JOURNAL OF MODERN MEDICINE & HEALTH, vol. 28, no. 8, 30 April 2012 (2012-04-30), pages 1142 and 1143
    STUART A. RUSHWORTH ET AL.: "Identification of Bruton' s tyrosine kinase as a therapeutic target in acute myeloid leukemia", BLOOD, vol. 123, no. 10, 4 December 2013 (2013-12-04), pages 1229 - 1238, XP055278268
    STUART A. RUSHWORTH ET AL.: "Identification of Bruton' s tyrosine kinase as a therapeutic target ir acute myeloid leukemia", BLOOD, vol. 123, no. 10, 4 December 2013 (2013-12-04), pages 1229 - 1238, XP055278272
    YI, LIEFANG ET AL.: "Clinical significance of FLT3 internal tandem duplication mutation in acute myeloid leukemia", DETECTION AND CLINICAL SIGNIFICANCE OF FLT3 INTERNAL TANDEM DUPLICATION MUTATION IN ACUTE MYELOID LEUKEMIA, vol. 30, no. 4, 31 August 2009 (2009-08-31), pages 453 - 455

Cited By (0)

    Publication numberPublication dateAssigneeTitle